Hospital
Mayo Clinic Hospital-Rochester
Mayo Clinic Hospital-Rochester was paid $11.46M by Medicaid between Jan 2018 and Dec 2024, across 124 billing codes. Its largest line is 99285, emergency room visit (most serious) — 46% of everything it billed.
33Billing provider infoMAYO CLINIC HOSPITAL-ROCHESTER
ROCHESTER, MN 55902
ROCHESTER, MN 55902
33aNPI1841266194assigned 02/27/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$11.46M
24GClaims176,584
24DCodes billed124
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Minnesota
Rank by total paid#19 of 36
Median peer was paid$11.46M
This provider vs. median1.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official DAHLEN, DENNIS controls 11+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 21,784 | $562K | |
| 2019 | 21,968 | $1.37M | |
| 2020 | 17,500 | $961K | |
| 2021 | 27,938 | $1.75M | |
| 2022 | 30,195 | $2.18M | |
| 2023 | 31,869 | $2.32M | |
| 2024incomplete | 25,330 | $2.31M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 46% | 13,879 | 12,781 | $5.26M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 21% | 12,529 | 11,855 | $2.37M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 8.9% | 3,990 | 3,676 | $1.02M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 3.4% | 4,648 | 4,122 | $386K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 2.4% | 1,603 | 1,408 | $271K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.2% | 2,605 | 2,540 | $253K |
| 67028 | Intravitreal injection of a pharmacologic agent | 1.9% | 876 | 746 | $218K |
| 36415 | Collection of venous blood by venipuncture | 1.7% | 21,382 | 18,989 | $190K |
| G0378 | Hospital observation service, per hour | 1.2% | 3,247 | 1,290 | $140K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,504 | 1,438 | $95K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 20,409 | 17,619 | $92K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 340 | 333 | $90K |
112 more codes
| 77080 | <1% | 156 | $72K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 3,542 | $70K |
| J0248 | Injection, remdesivir, 1 mg | <1% | 117 | $66K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 3,420 | $66K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 828 | $52K |
| D0150 | Comprehensive oral evaluation - new or established patient | <1% | 56 | $50K |
| Q0222 | Injection, bebtelovimab, 175 mg | <1% | 38 | $49K |
| M0222 | Intravenous injection, bebtelovimab, includes injection and post administration monitoring | <1% | 198 | $46K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 316 | $42K |
| M0247 | Intravenous infusion, sotrovimab, includes infusion and post administration monitoring | <1% | 207 | $41K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 455 | $31K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,504 | $31K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 4,551 | $30K |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 104 | $30K |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 89 | $28K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,493 | $28K |
| 95782 | <1% | 37 | $25K | |
| 87631 | <1% | 851 | $23K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 27 | $22K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 819 | $22K |
| 93325 | <1% | 710 | $20K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 104 | $16K |
| 80053 | Comprehensive metabolic panel | <1% | 1,687 | $13K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 296 | $13K |
| M0239 | Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring | <1% | 77 | $12K |
| 97597 | <1% | 90 | $11K | |
| 82565 | <1% | 1,117 | $8K | |
| A9270 | Non-covered item or service | <1% | 2,655 | $8K |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 53 | $8K |
| 91200 | <1% | 70 | $8K | |
| D9420 | <1% | 57 | $7K | |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 540 | $7K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,684 | $5K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 24 | $5K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 171 | $5K |
| 93320 | <1% | 27 | $5K | |
| 83605 | <1% | 739 | $5K | |
| J0475 | Injection, baclofen, 10 mg | <1% | 12 | $5K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 83 | $4K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 76 | $4K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 3,272 | $4K |
| J2704 | Injection, propofol, 10 mg | <1% | 14,642 | $4K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 62 | $4K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 3,361 | $4K |
| 82947 | <1% | 2,273 | $4K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 3,028 | $3K |
| C9257 | Injection, bevacizumab, 0.25 mg | <1% | 184 | $3K |
| 71045 | Radiologic examination, chest; single view | <1% | 435 | $3K |
| 83935 | <1% | 106 | $3K | |
| D1120 | Dental cleaning, child | <1% | 25 | $3K |
| D1206 | Topical application of fluoride varnish | <1% | 26 | $3K |
| 0753T | <1% | 328 | $3K | |
| 82948 | <1% | 1,082 | $2K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 3,233 | $2K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 6,375 | $2K |
| 85610 | <1% | 720 | $2K | |
| 82248 | <1% | 655 | $2K | |
| 77336 | <1% | 33 | $2K | |
| C1769 | Guide wire | <1% | 914 | $1K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 2,716 | $1K |
| 62370 | <1% | 12 | $1K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 4,206 | $1K |
| J3490 | Unclassified drugs | <1% | 1,094 | $1K |
| 84484 | <1% | 127 | $1K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 69 | $1K |
| 83735 | <1% | 249 | $1K | |
| 36591 | <1% | 95 | $894.09 | |
| 88342 | <1% | 105 | $815.35 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 514 | $785.28 |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 13 | $634.62 |
| 84132 | <1% | 197 | $604.39 | |
| 80051 | <1% | 672 | $530.40 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 351 | $483.49 |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 57 | $482.58 |
| 85027 | <1% | 141 | $472.28 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 725 | $422.63 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,708 | $341.52 |
| 83690 | <1% | 84 | $324.79 | |
| 84520 | <1% | 759 | $324.34 | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 15 | $318.94 |
| 87634 | <1% | 28 | $302.33 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 740 | $265.35 |
| 84295 | <1% | 64 | $242.57 | |
| 84450 | <1% | 66 | $220.74 | |
| 87070 | <1% | 62 | $219.27 | |
| 81001 | <1% | 106 | $217.01 | |
| 82077 | <1% | 13 | $215.46 | |
| 82803 | <1% | 25 | $213.86 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 248 | $207.30 |
| 74018 | <1% | 38 | $205.64 | |
| 84702 | <1% | 58 | $201.99 | |
| 84075 | <1% | 47 | $126.81 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,173 | $117.27 |
| 88313 | <1% | 13 | $116.14 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 27 | $100.38 |
| 87205 | <1% | 27 | $74.25 | |
| 82247 | <1% | 26 | $34.99 | |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 34 | $34.05 |
| 77091 | <1% | 14 | $30.64 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 28 | $18.54 |
| 87206 | <1% | 17 | $16.71 | |
| 81003 | <1% | 12 | $14.82 | |
| 88307 | <1% | 15 | $13.02 | |
| 85379 | <1% | 13 | $10.52 | |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | <1% | 46 | $7.42 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 404 | $1.10 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 280 | $0.03 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 132 | $0.02 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 13 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 15 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 27 | $0.00 |
| C9290 | Injection, bupivacaine liposome, 1 mg | 0% | 18 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDAHLEN, DENNIS (CHIEF FINANCIAL OFFICER)
| Provider | Location | Paid |
|---|---|---|
| Mayo Clinic | Rochester, MN | $74.39M |
| Mayo Foundation for Medical Education & Research | Rochester, MN | $2.83M |
| Mayo Clinic Hospital-Rochester | Onalaska, WI | $832K |
| Mayo Clinic Hospital-Rochester | Fairmont, MN | $682K |
| Mayo Foundation for Medical Education & Research | Rochester, MN | $320K |
| Mayo Clinic Hospital-Rochester | Rochester, MN | $193K |
| Mayo Clinic Hospital-Rochester | Rochester, MN | $181K |
| Mayo Clinic Hospital-Rochester | Albert Lea, MN | $52K |
| Mayo Clinic Hospital-Rochester | Owatonna, MN | $15K |
| Mayo Clinic Hospital-Rochester | Decorah, IA | $423.45 |
| Mayo Clinic | Rochester, MN | $0.00 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.